Hidden rebates mask true prices of pharmaceutical drugs in the market
Washington
COMPETITION can work in the pharmaceutical industry in counter-intuitive ways: New drugs typically enter the market with higher price tags than existing medications, and then all the prices rise. In the case of Gleevec, a breakthrough cancer drug approved in 2001, the advent of pricier and more potent competitors seemed to speed up the older drug's list price increases.
What remains frustratingly opaque, however, is precisely what the prices are. The drug industry commonly points out that list prices are essentially fiction; a drug's real price is a secret number that pharmaceutical companies develop in negotiations with the firms that provide prescription drug benefits. List prices are a proxy, a starting point against which rebates are applied - but drug companies refuse to disclose the rebates and discounts, leaving the exact, "real" price basically mysterious.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices
Dying salmon trouble Norway’s vast fish-farm industry
Fast-fashion giant Shein wants to sell skincare, toothpaste and toys, too
Billionaire Geiger is said to near US$7 billion L’Occitane buyout